Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma
Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC FORT LEE, N.J., Oct. 14, 2026 (GLOBE...
Atlas-HRT.com Launches Online TRT and Men’s Health Platform in Florida, as Men Over 40 Look for Clear Answers on Testosterone Therapy